• The Lead Podcast - Episode 80
    Nov 7 2024

    This episode is a discussion of the paper entitled, "Catheter Ablation versus Advanced Therapy for Patients with Severe Heart Failure and Ventricular Electrical Storm."


    https://www.hrsonline.org/education/TheLead
    https://doi.org/10.1016/j.hrthm.2024.09.045


    Host Disclosure(s):
    W.Sauer: Honoraria/Speaking/Consulting: Biotronik, Biosense Webster, Inc., Abbott, Boston Scientific, Research: Medtronic

    Contributor Disclosure(s):
    R. Kerley: Nothing to disclose.
    A. Desai: Research: Novartis, Bayer Healthcare Pharmaceuticals, Abbott Medical, AstraZeneca, Honoraria/Speaking/Consulting: Novartis, Abbott, AstraZeneca, Regerneron, Alnylam Pharmaceuticals, Bayer Healthcare Pharmaceutricals, Cytokinetics, AxonTherapies, Avidity Biosciences, Medpace, Merck, New Amsterdam Pharma, Parexel, Roche Diagnostics, GlacoSmithKline, NovoNordisk, Veristat, Verily/Google, Zydus, River2Renal, Membership on Advisory Committees: BioFourmis

    Show more Show less
    17 mins
  • The Lead Podcast - Episode 79
    Oct 17 2024

    Join host Deepthy Varghese, MSN, ACNP, FNP, as she discusses Managing Data Overload: AI Wearables and Apps with article author Hawkins Gay, MD, MPH. This article was published simultaneously with HRX 2024, and the interview is brought to you live from the meeting in Atlanta, Georgia.


    https://www.hrsonline.org/education/TheLead
    https://www.heartrhythmjournal.com/article/S1547-5271(24)03114-X/abstract


    Host Disclosure(s):
    D. Varghese: Nothing to disclose.

    Contributor Disclosure(s):
    H. Gay: Nothing to disclose.

    Show more Show less
    16 mins
  • The Lead Podcast - Episode 78
    Oct 10 2024

    In this episode of The Lead, brought to you live from HRX, Deepthy Varghese interviews author Sana Al-Khatib on two of her recent publications.


    https://www.hrsonline.org/education/TheLead
    https://www.heartrhythmjournal.com/article/S1547-5271(24)03110-2/abstract
    https://www.heartrhythmjournal.com/article/S1547-5271(24)02380-4/fulltext


    Host Disclosure(s):
    D. Varghese: Nothing to disclose.

    Contributor Disclosure(s):
    S. Al-Khatib: Other Relationships: American Heart Association

    Show more Show less
    13 mins
  • The Lead Podcast - Episode 77
    Sep 19 2024

    Join us for another episode of The Lead!


    https://www.hrsonline.org/education/TheLead
    https://jamanetwork.com/journals/jama/article-abstract/2823283


    Host Disclosure(s):
    J. Chyou: Honoraria/Speaking/Consulting: American Heart Association, McGraw Hill, Medtronic, Research: American Heart Association, Membership on Advisory Committees: American Heart Association

    Contributor Disclosure(s):
    C. Cheung: Nothing to disclose.
    P. Sanders: Membership on Advisory Committees: Boston Scientific, Medtronic PLC, Pacemate, CathRx, Research: Abbott, Becton Dickinson, Boston Scientific, CathRx, Medtronic, Pacemate.

    Show more Show less
    18 mins
  • HRX Innovation Hub Podcast, powered by CardiacRMS: CIED Heart Failure Monitoring for EPs
    Sep 13 2024

    Moderated by Rebecca Yapejian with CardiacRMS, this podcast is a dynamic discussion between Jagmeet P. Singh, MD, PhD, FHRS and Suneet Mittal, MD, FHRS, on the current and future state of CIED Remote Monitoring for Electophysiologists.

    Faculty

    Suneet Mittal MD, FHRS
    Jagmeet Singh, MD, PhD, FHRS
    Rebecca Yapejian, BS, BSN, MSN, APRN, FNP, CCDS, CardiacRMS

    Show more Show less
    34 mins
  • The Lead Podcast - Episode 76
    Sep 12 2024

    Join moderator Melissa Middeldorp as she discusses the NEJM article Asundexian versus Apixaban in Patients with Atrial Fibrillation with Christopher C Cheung, MD, MPH and Prashanthan Sanders, MBBS, PhD, FHRS at HRS2024 in Atalnta. This episode is brought to you live from the HRSTV Studio and comes with bonus video footage.


    https://www.hrsonline.org/education/TheLead
    https://www.nejm.org/doi/full/10.1056/NEJMoa2407105


    Host Disclosure(s):
    M. Middeldorp: Nothing to disclose.

    Contributor Disclosure(s):
    C. Cheung: Nothing to disclose.
    P. Sanders: Membership on Advisory Committees: Boston Scientific, Medtronic PLC, Pacemate, CathRx, Research: Abbott, Becton Dickinson, Boston Scientific, CathRx, Medtronic, Pacemate.

    Show more Show less
    11 mins
  • The Lead Podcast - Episode 75
    Aug 22 2024

    Dr. Michael S. Lloyd, MD, FHRS, Emory University is joined by Lucas V. A. Boersma, MD, PhD, St Antonius Hospital, and Michael Hoskins, MD, New Mexico Heart Institute to discuss the Pulmonary Vein Isolation With or Without Left Atrial Appendage Ligation in Atrial Fibrillation The aMAZE Randomized Clinical Trial.

    https://jamanetwork.com/journals/jama/fullarticle/2816924
    https://www.hrsonline.org/education/TheLead


    Host Disclosure(s):
    M. Lloyd: Honoraria/Speaking/Consulting: Medtronic, Membership on Advisory Committees: Boston Scientific

    Contributor Disclosure(s):
    L. Boersma: Honoraria/Speaking/Consulting: Boston Scientific, Adagio Medical, Medtronic, Honoraria/Speaking/Teaching: Acutus Medical, KODEX-EPD
    M. Hoskins: Nothing to disclose.

    Show more Show less
    24 mins
  • The Lead Podcast - Episode 74
    Aug 15 2024

    Niraj Sharma, MD, FHRS, Northside Hospital is joined by Rhea Pimentel, BChir, MD, FHRS, University of Kansas Health System and Usman Siddiqui, MD, Florida Cardiology Advent Health Systems, Orlando, to discuss how the FLUTFIB study aimed to assess the incidence, duration, timing, and symptoms of atrial fibrillation (AF) after cavotricuspid isthmus (CTI) ablation in patients with atrial flutter (AFL). The study included 100 patients with AFL, who received implantable loop recorders for continuous AF monitoring following CTI ablation. Over a median follow-up of 24 months, 77% of patients experienced AF episodes, typically occurring around 180 days post-ablation. Most AF episodes lasted over an hour, and about half of the patients reported symptoms. Baseline characteristics and risk scores (HATCH and CHA2DS2-VASc) did not predict AF development. Oral anticoagulation was discontinued in 32% of patients during follow-up but was restarted in 15% after AF detection. No strokes or transient ischemic attacks were recorded. This study, the largest of its kind, underscores the high incidence of often asymptomatic AF after AFL ablation and provides insights for anticoagulation management post-ablation.

    https://www.hrsonline.org/education/TheLead


    Host Disclosure(s):
    N. Sharma: Nothing to disclose.

    Contributor Disclosure(s):
    U. Siddiqui: Honoraria/Speaking/Teaching: Abbott Medical, Acutus Medical Inc., Impulse Dynamics USA
    R. Pimentel: Honoraria/Speaking/Consulting: American College of Cardiology Foundation, Honoraria/Speaking/Teaching: Medtronic, Boston Scientific, Abbott Medical, Membership on Advisory Boards: Biosense Webster


    This episode has .25 ACE credits associated with it. If you want credit for listening to this episode, please visit the episode page on HRS365 https://www.heartrhythm365.org/URL/TheLeadEpisode74

    Show more Show less
    18 mins